Clinical Trials Directory

Trials / Recruiting

RecruitingNCT07298889

High PEEP in Noninvasive Ventilation Patients With Pneumonia or ARDS

Effect of High Versus Low Positive End-Expiratory Pressure on Intubation-Free Survival in Patients With Pneumonia or ARDS Receiving Noninvasive Ventilation: A Multicenter Randomized Controlled Trial

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
706 (estimated)
Sponsor
Chongqing Medical University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Noninvasive ventilation is commonly employed in patients with pneumonia or acute respiratory distress syndrome (ARDS) and has been shown to reduce the need for intubation and invasive mechanical ventilation. However, the rate of noninvasive ventilation failure remains substantial, at approximately 40%. Compared with patients in whom noninvasive ventilation succeeds, those who experience noninvasive ventilation failure have a higher likelihood of mortality during their intensive care unit or hospital stay. Therefore, improving the success rate of noninvasive ventilation is clinically important. In patients with lung consolidation receiving invasive mechanical ventilation, high positive end-expiratory pressure (PEEP) can improve oxygenation. Noninvasive ventilation operates on similar physiological principles and can also deliver high PEEP via a mask interface. Nevertheless, there is limited evidence regarding the use of high PEEP during mask-delivered noninvasive ventilation. This study aimed to evaluate whether high PEEP can increase intubation-free survival in patients with pneumonia or ARDS who are treated with noninvasive ventilation.

Conditions

Interventions

TypeNameDescription
PROCEDUREThe level of PEEP during noninvasive ventilationIn patients receiving noninvasive ventilation, participants will be randomly assigned to either a low or a high PEEP group. In the high PEEP group, PEEP will be set between 10 and 15 cmH2O. In the low PEEP group, PEEP will be maintained at 5 cmH2O.

Timeline

Start date
2026-01-04
Primary completion
2029-12-31
Completion
2029-12-31
First posted
2025-12-23
Last updated
2026-01-07

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT07298889. Inclusion in this directory is not an endorsement.